Autologous Anti-CD19 AbTCR-expressing T-lymphocytes EB103

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding an antibody-T-cell-receptor (AbTCR) composed of a CD19-binding domain derived from an antibody fragment antigen binding (Fab) region and an effector domain derived from human gamma/delta TCR, and a co-stimulatory molecule composed of a CD19-binding domain derived from a single-chain variable fragment (scFv) and a co-stimulatory domain derived from a human co-stimulatory receptor, with potential immunostimulating and antineoplastic activities. Upon administration of the autologous anti-CD19 AbTCR-expressing T-lymphocytes EB103, both the AbTCR moiety and the co-stimulatory molecule recognize and bind to CD-19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.

**Synonyms:** - Autologous Anti-CD19 AbTCR-expressing T-cells EB103 - Autologous Anti-CD19 Antibody Redirected T Cells with Endogenous Modular Immune Signaling EB103 - Autologous CD19-redirected ARTEMIS T Cells EB103 - EB 103 - EB-103 - EB103